Biologics company sells shares, registers with SEC

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ JUAN GAERTNER/SCIENCE PHOTO LIBRARY
(Image: Getty/ JUAN GAERTNER/SCIENCE PHOTO LIBRARY

Related tags: T cell, T cell receptor, T cells, Biologics, SEC, Stock exchange, Stock, IPO, phase I

Harpoon offers to sell shares of its common stock in its proposed IPO after registering a statement with the SEC while developing T-Cell engagers.

Harpoon Therapeutics filed a registration statement with the US Securities and Exchange Commission (SEC) in relation to its proposed initial public offering (IPO). Harpoon is currently in a quiet period and was unable to comment on the details of its IPO at this time.

Price and quantity of common stock shares have yet to set.

While Harpoon has registered a statement relating to these securities and it has been filed with the SEC, it has not yet become effective.

The clinical-stage immunotherapy company, specializes in the development of T cell engagers​.

Harpoon is working with CMC Biologics to develop and manufacture​ its three lead biologic candidates: HPN424, HPN536, and HPN217. CMC is using its CHEF1 Expression Platform to create clinical and commercial cell lines for the biologics.

The drug candidates were developed through Harpoon’s Tri-specific T-Cell activating construct (TriTEC) platform. The company has plans on moving HPN424 into Phase I trials through the work being done with CMC Biologics. 

Related news

Show more

Related products

show more

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars